Name: Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies (Volume 15) (Cancer Sensitizing Agents for Chemotherapy, Volume 15) (en Inglés)
Price: 169370.00 CLP
Availability: InStock
ISBN: 9780128215678

portada Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies (Volume 15) (Cancer Sensitizing Agents for Chemotherapy, Volume 15) (en Inglés)

Formato

Libro Físico

Editorial

Academic Press Inc

Año

2021

Idioma

Inglés

N° páginas

828

Encuadernación

Tapa Dura

ISBN13

9780128215678

N° edición

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies (Volume 15) (Cancer Sensitizing Agents for Chemotherapy, Volume 15) (en Inglés)

Libro Físico

$ 169.370

$ 282.290

Ahorras: $ 112.920

40% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Viernes 14 de Junio y el Miércoles 26 de Junio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies (Volume 15) (Cancer Sensitizing Agents for Chemotherapy, Volume 15) (en Inglés)"

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood.